Evidence map›Paper›PMID 38664245›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Bergapten enhances mitophagy to regulate intestinal barrier and Th17/Treg balance in mice with Crohn's disease-like colitis via PPARγ/NF-κB signaling pathway.

Ling Xu, Bin Zhao, Haihe Cheng, Gang Li, Yan Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ling XuDepartment of Anorectal Surgery, Zhangjiagang Hospital Affiliated to Soochow University, No.68 West Jiyang Road, Zhangjiagang, Suzhou, 215600, Jiangsu, China.
Bin ZhaoDepartment of Gastroenterology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, 215600, Jiangsu, China.
Haihe ChengDepartment of Anorectal Surgery, Zhangjiagang Hospital Affiliated to Soochow University, No.68 West Jiyang Road, Zhangjiagang, Suzhou, 215600, Jiangsu, China.
Gang LiDepartment of Anorectal Surgery, Zhangjiagang Hospital Affiliated to Soochow University, No.68 West Jiyang Road, Zhangjiagang, Suzhou, 215600, Jiangsu, China.
Yan SunDepartment of Anorectal Surgery, Zhangjiagang Hospital Affiliated to Soochow University, No.68 West Jiyang Road, Zhangjiagang, Suzhou, 215600, Jiangsu, China. yansunsun@126.com.
Soochow University · CNZhangjiagang First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate whether bergapten (BG), a furanocoumarin phytohormone, holds promise for Crohn's disease (CD)-like colitis treatment and to preliminarily explore its potential mechanisms. 2,4,6-Trinitrobenzenesufonic acid (TNBS)-treated mice were applied to establish an in vivo research model, and BG was administered with different concentrations. The status of mice in each group was evaluated by disease activity index (DAI), and the severity was evaluated by pathological sections. The intestinal barrier was assessed by measuring in vivo intestinal permeability, peripheral blood intestinal fatty acid-binding protein (I-FABP) levels, epithelial resistance values, and tight junction protein levels. Markers were then used to assess Th17/Treg levels, mitophagy, and the peroxisome proliferator-activated receptor (PPAR)γ/ nuclear factor kappa B (NF-κB) signaling pathway. BG significantly reduced colon tissue damage in a concentration-dependent manner. DAI scores showed that the loose feces, occult blood, and weight loss of mice in the BG treatment were significantly reduced, and pathological section results revealed reduced inflammatory infiltration and fibrosis. Reduced serum FITC-dextran and I-FABP and increased levels of epithelial resistance and tight junction proteins support that the intestinal barrier was protected upon BG. The proportion of Th17 in mesenteric lymph nodes increased while Treg decreased in the model group. BG treatment effectively reduced the conversion of Treg to Th17. Additionally, BG was found to enhance mitophagy and activate the PPARγ/NF-κB signaling. BG demonstrates promising effects in ameliorating intestinal barrier damage and Th17/Treg imbalance in a murine model of CD-like colitis, while also promoting intracellular mitophagy. The PPARγ/NF-κB signaling pathway may serve as a key mediator of BG's regulatory mechanisms.

Indexed as

ColitisCrohn DiseaseIntestinal MucosaMitophagyNF-kappa BPPAR gammaSignal TransductionTh17 CellsT-Lymphocytes, RegulatoryAnimalsColonDisease Models, AnimalFatty Acid-Binding ProteinsMaleMiceMice, Inbred BALB CFatty Acid-Binding ProteinsNF-kappa BPPAR gammaPparg protein, mouseTrinitrobenzenesulfonic AcidCrohn’s diseaseInflammatory bowel diseaseIntestinal barrierPPART cell

Identifiers

PMID38664245
OpenAlexW4395669949

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.